ConductScience.org, home
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
API referenceFor AI assistants

Trial · NCT01968109

Participant flow93

How many started, completed or left each group, period by period.

1 to 20 of 93

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Overall StudySTARTEDBMS-986016 (Relatlimab) Monotherapy 20 Milligram (mg) (Part A)5
Overall StudySTARTEDBMS-986016 (Relatlimab) Monotherapy 80 Milligram (mg) (Part A)4
Overall StudySTARTEDBMS-986016 (Relatlimab) Monotherapy 240 Milligram (mg) (Part A)4
Overall StudySTARTEDBMS-986016 (Relatlimab) Monotherapy 800 Milligram (mg) (Part A/A1)12
Overall StudySTARTEDCombination-Escalation-BMS-986016 (Relatlimab)/Nivolumab (20 mg/80 mg) (Part B)7
Overall StudySTARTEDCombo-esc--BMS-986016 (Relatlimab)/Nivolumab (20 mg/240 mg (Part B)9
Overall StudySTARTEDCombo-esc--BMS-986016 (Relatlimab)/Nivolumab (80 mg/240 mg) (Part B)8
Overall StudySTARTEDCombo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/240 mg) (Part B)8
Overall StudySTARTEDCombo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/240 mg) (Part B)8
Overall StudySTARTEDCombo-esc--BMS-986016 (Relatlimab)/Nivolumab (160 mg/480 mg) (Part B)8
Overall StudySTARTEDCombo-esc--BMS-986016 (Relatlimab)/Nivolumab (240 mg/480 mg) (Part B)8
Overall StudySTARTEDCombo-esc--BMS-986016 (Relatlimab)/Nivolumab (320 mg/480 mg) (Part B)8
Overall StudySTARTEDCombo-esc--BMS-986016 (Relatlimab)/Nivolumab (480 mg/480 mg) (Part B)7
Overall StudySTARTEDCombo-esc--BMS-986016 (Relatlimab)/Nivolumab (960 mg/480 mg) (Part B)17
Overall StudySTARTEDCombo-esc--BMS-986016 (Relatlimab)/Nivolumab (1440 mg/480 mg) (Part B)19
Overall StudySTARTEDNSCLC IO Naive-80/240 (Part C)24
Overall StudySTARTEDMEL 1L-80/240 (Part C)66
Overall StudySTARTEDRCC IO Naive-80/240 (Part C)26
Overall StudySTARTEDSCCHN IO Naive-80/240 (Part C)65
Overall StudySTARTEDHCC IO Naive-80/240 (Part C)63

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01968109/flow

API referenceFor AI assistants